Premium
Green tea polyphenol epigallocatechin‐3‐gallate enhances 5‐fluorouracil‐induced cell growth inhibition of hepatocellular carcinoma cells
Author(s) -
Yang XueWei,
Wang XiaoLi,
Cao LiangQi,
Jiang XiaoFeng,
Peng HePing,
Lin ShaoMang,
Xue Ping,
Chen De
Publication year - 2012
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/j.1872-034x.2011.00947.x
Subject(s) - epigallocatechin gallate , cell growth , cancer research , apoptosis , downregulation and upregulation , ampk , growth inhibition , chemistry , cell culture , protein kinase b , gallate , small interfering rna , microbiology and biotechnology , mtt assay , hepatocellular carcinoma , pharmacology , polyphenol , medicine , biochemistry , biology , protein kinase a , enzyme , transfection , antioxidant , genetics , gene
Aim: 5‐Fluorouracil (5‐FU) is one of the most commonly used chemotherapeutic drugs. Resistance to 5‐FU is a major cause of chemotherapy failure in advanced‐stage hepatocellular carcinoma (HCC). Green tea polyphenol Epigallocatechin‐3‐gallate (EGCG) plays a critical role in growth inhibition and apoptotic induction in HCC cell lines. The aim of this study is to investigate whether EGCG can enhance 5‐FU‐induced cell growth inhibition and to explore its potential mechanisms. Methods: 3‐(4,5‐Dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) assay was used to evaluate cell growth. Western blotting analysis was performed to detect the proteins expression in Hep3B cells. Small interfering RNA was used to suppress cyclooxygenase‐2 (COX‐2) expression. Furthermore, enzyme linked immunosorbent assay was used to test the prostaglandin E 2 (PGE 2 ) production in cell cultures. Results: Epigallocatechin‐3‐gallate augmented the anti‐tumor effect of 5‐FU in Hep3B cells. Significant difference was observed between the treated groups and the control group ( P < 0.05). EGCG (its concentrations at over 5 µmol/L) combined with 5‐FU presented a synergic effect. Furthermore, the combination of EGCG and 5‐FU abrogated the COX‐2 overexpression and PGE 2 secretion induced by 5‐FU. The upregulation of COX‐2 expression decreased the phosphorylation of Akt (Thr 308 ) expression. These appeared to be followed by the AMPK hyperactivation. Conclusion: Epigallocatechin‐3‐gallate sensitizes HCC cells to 5‐FU antitumor activity, and the combination of EGCG and 5‐FU exhibits synergism in chemo‐resistant cancer cells. The results suggest potential novel therapies for the treatment of advanced‐stage liver cancer.